Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...
It also reported retail investors were eager purchasers of Tesla (NASDAQ: TSLA ), Broadcom (NASDAQ: AVGO) and Apple (NASDAQ: ...
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They currently have a ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a ...
Research analysts at StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a note issued to investors on Tuesday. The brokerage set a “hold” rating on ...
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $256.56 million and impressive gross profit margins of 93.62%, disclosed through a social media post ...
Highlights faulty FDA review WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provides an update on the tradipitant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback